Multiple myeloma
Genomics of Multiple Myeloma
... Multiple myeloma (MM) is characterized by the accumulation (usually) of tumor plasma cells (PCs) within the bone marrow compartment. Clinically, MM is characterized by a wide heterogeneity both for clinical ...
7
Bone marrow mesenchymal stem cells are abnormal in multiple myeloma.
... in multiple myeloma (MM), we studied bone marrow mesenchymal stem cells (BMMSCs), the only long-lived cells of the bone marrow microenvironment, by gene expression with Affymetrix arrays and phenotypic and ...
36
In vitro expansion of gamma delta T cells with anti-myeloma cell activity by Phosphostim and IL-2 in patients with multiple myeloma.: Anti-myeloma activity of amplified gamma delta T cells
... References Alsayed, Y., Ngo, H., Runnels, J., Leleu, X., Singha, U.K., Pitsillides, C.M., Spencer, J.A., Kimlinger, T., Ghobrial, J.M., Jia, X., Lu, G., Timm, M., Kumar, A., Cote, D., Veilleux, I., Hedin, K.E., Roodman, ...
29
Expressed fusion gene landscape and its impact in multiple myeloma
... 4 Multiple myeloma is a plasma cell malignancy characterized by recurrent IgH translocations and well described genomic ...in multiple myeloma has been described, landscape of expressed fusion ...
11
Resistance to the proteasome inhibitors: Lessons from multiple myeloma and mantle cell lymphoma
... 2.1 Multiple myeloma MM is a plasma cell malignancy with bone marrow (BM) infiltration of clonal cells and monoclonal immunoglobulin protein in the serum and/or urine of ...affect multiple signalling ...
32
Deciphering the chronology of copy number alterations in Multiple Myeloma
... Abstract Multiple myeloma (MM) and its precursor condition MGUS are characterized by chromosomal aberrations. Here, we comprehensively characterize the order of occurrence of these complex genomic events ...
11
Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group.
... J Hillengass 1,2 , LA Moulopoulos 3 , S Delorme 2 , V Koutoulidis 3 , J Mosebach 2 , T Hielscher 4 , M Drake 5 , SV Rajkumar 6 , B Oestergaard 7 , N Abildgaard 7 , M Hinge 7 , T Plesner 8 , Y Suehara 9 , K Matsue 9 , N ...
6
A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines.
... These 206 patients were treated with Vincristine, Adriamicyne and Dexamethasone (VAD), high dose Melphalan (HDM) and autologous stem cell transplantation (ASCT) (27) and were termed in the following ...
69
Multiple myeloma treatment at relapse after autologous stem cell transplantation: a practical analysis
... Over the past decade, significant advances have been made in the field of multiple myeloma. Introduction of the so-called novel agents, proteasome inhibitors (PI) and immunomodulatory drugs (IMiD), and ...
27
Cancer/Testis genes in multiple myeloma: expression patterns and prognosis value determined by microarray analysis.: Expression of cancer-testis genes in multiple myeloma
... FIGURE 2: Gene expression of 10 CT genes measured by pan genomic Affymetrix HG-U133 Set arrays. Histograms show the expression level of 10 CT genes in five testis samples, seven normal memory B cell (MB) samples, seven ...
34
Gene expression profiling and real-time PCR analyses identify novel potential cancer-testis antigens in multiple myeloma.: Novel cancer-testis genes in multiple myeloma
... in multiple myeloma, we used Affymetrix HG-U133 gene expression profiles of 5 testis, 64 primary myeloma cell (MMC) and 24 normal tissue (NT) ...
16
Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant
... investigate the interaction between CHIP, transplant and IMiDs on outcomes in multiple myeloma. Methods Cohort. Following institutional review board (IRB) approval, we collected the clinical data and all ...
10
Determining therapeutic susceptibility in multiple myeloma by single-cell mass accumulation
... Primary multiple myeloma spe- cimens were collected from patients at the Dana-Farber Cancer Institute upon provision of informed consent under a tissue banking protocol (Dana-Farber Harvard Cancer Center ...
13
Antioxidant Defenses Confer Resistance to High Dose Melphalan in Multiple Myeloma Cells
... Background: Multiple myeloma (MM) is the second most common hematological cancer after ...human myeloma cell lines (HMCLs) and primary myeloma cells from ...
21
Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network.
... Cytomegalovirus PIs and high-dose therapy increase the risk for cytomega- lovirus (CMV) reactivation or infection. Such infections not rarely remain unrecognized. For diagnosis of CMV infec- tion, polymerase chain ...
19
Logic programming reveals alteration of key transcription factors in multiple myeloma
... Conclusion In this study, we used a specific approach to study and understand the heterogeneous gene expression profiles of approximately 600 multiple myeloma (MM) patients. Our primary goal was to provide ...
13
Inhibition of Aurora-kinases for tailored risk adapted treatment of multiple myeloma.
... including multiple myeloma 25 . Aurora-A and -B are expressed in all myeloma cell lines and proliferating 36 (non-malignant) plasmablastic cells, and are significantly higher expressed in both of ...
38
Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma
... 8. Halvarsson B-M, Wihlborg A-K, Ali M, Lemonakis K, Johnsson E, Niroula A, et al. Direct evidence for a polygenic etiology in familial multiple myeloma. Blood Adv. 2017;1:619 –23. 9. Wei X, Calvo-Vidal MN, ...
8
Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma
... Abstract Car filzomib, a selective proteasome inhibitor (PI), is approved for the treatment of patients with relapsed or refractory multiple myeloma (MM). Combination regimens incorporating a PI and ...
18
The effects of forodesine in murine and human multiple myeloma cells
... cited. Multiple myeloma (MM) is the second most commonly diagnosed hematological malignancy, characterized by a monoclonal proliferation of malignant cells in the bone ...
8